Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. / Myhr, K M; Ross, C; Nyland, H I; Bendtzen, K; Vedeler, C A.

I: Neurology, Bind 55, Nr. 10, 28.11.2000, s. 1569-72.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Myhr, KM, Ross, C, Nyland, HI, Bendtzen, K & Vedeler, CA 2000, 'Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive', Neurology, bind 55, nr. 10, s. 1569-72.

APA

Myhr, K. M., Ross, C., Nyland, H. I., Bendtzen, K., & Vedeler, C. A. (2000). Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology, 55(10), 1569-72.

Vancouver

Myhr KM, Ross C, Nyland HI, Bendtzen K, Vedeler CA. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology. 2000 nov. 28;55(10):1569-72.

Author

Myhr, K M ; Ross, C ; Nyland, H I ; Bendtzen, K ; Vedeler, C A. / Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. I: Neurology. 2000 ; Bind 55, Nr. 10. s. 1569-72.

Bibtex

@article{5cc14f68efb349899e74c4bd4a853746,
title = "Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive",
abstract = "Sera from patients with MS treated with recombinant interferon (rIFN) alpha-2a, rIFNbeta-1a, or rIFNbeta-1b were analyzed for cross-reacting neutralizing antibodies (NAB). Because cross-reactivity was not found, switching treatment from rIFNbeta-1a or rIFNbeta-1b to rIFNalpha-2a might provide a secondary treatment response in patients with NAB to rIFNbeta-1a or rIFNbeta-1b. A positive treatment response also might be achieved by switching NAB rIFNalpha-2a-positive patients to rIFNbeta-1a or rIFNbeta-1b.",
author = "Myhr, {K M} and C Ross and Nyland, {H I} and K Bendtzen and Vedeler, {C A}",
year = "2000",
month = nov,
day = "28",
language = "English",
volume = "55",
pages = "1569--72",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "10",

}

RIS

TY - JOUR

T1 - Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive

AU - Myhr, K M

AU - Ross, C

AU - Nyland, H I

AU - Bendtzen, K

AU - Vedeler, C A

PY - 2000/11/28

Y1 - 2000/11/28

N2 - Sera from patients with MS treated with recombinant interferon (rIFN) alpha-2a, rIFNbeta-1a, or rIFNbeta-1b were analyzed for cross-reacting neutralizing antibodies (NAB). Because cross-reactivity was not found, switching treatment from rIFNbeta-1a or rIFNbeta-1b to rIFNalpha-2a might provide a secondary treatment response in patients with NAB to rIFNbeta-1a or rIFNbeta-1b. A positive treatment response also might be achieved by switching NAB rIFNalpha-2a-positive patients to rIFNbeta-1a or rIFNbeta-1b.

AB - Sera from patients with MS treated with recombinant interferon (rIFN) alpha-2a, rIFNbeta-1a, or rIFNbeta-1b were analyzed for cross-reacting neutralizing antibodies (NAB). Because cross-reactivity was not found, switching treatment from rIFNbeta-1a or rIFNbeta-1b to rIFNalpha-2a might provide a secondary treatment response in patients with NAB to rIFNbeta-1a or rIFNbeta-1b. A positive treatment response also might be achieved by switching NAB rIFNalpha-2a-positive patients to rIFNbeta-1a or rIFNbeta-1b.

M3 - Journal article

VL - 55

SP - 1569

EP - 1572

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -

ID: 34101711